Product Description
A substance used to detect prostate cancer. It contains a monoclonal antibody that binds to prostate cells, linked to a substance that can bind radioisotopes. Capromab pendetide is combined with indium 111 and injected into the body. A gamma camera (a special camera that detects radioactivity) is used to find prostate cancer cells in the body. Capromab pendetide is a type of immunoconjugate. Also called ProstaScint. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/capromab-pendetide)
Mechanisms of Action: PSMA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Canada | Germany | Ireland | Italy
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|